An elite-growth healthcare technology business generating exceptional free cash flow despite GAAP losses, with four consecutive earnings beats and 47% revenue growth — but the stock has effectively reached the analyst consensus target, leaving thin upside and an 82% partner contract concentration that warrants caution at current prices.
Thesis pillars
- Elite Fcf Despite Gaap Losses↑Improving
- Partner Concentration Structural Risk↑Improving
- Hypergrowth Revenue Trajectory→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 3, 2026· older than 90 days
Hinge Health, Inc. (HNGE) Stock Analysis
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $120.87, but acceptable to hold if already in. Reasons: Concentration risk — Customer: partner contracts (82.0%); Analyst target reached - limited upside remaining.
Hinge Health delivers AI-powered musculoskeletal care through a digital platform serving self-insured employers, health plans, and Medicare Advantage populations with programs across 16 body areas. Revenue is earned primarily through per-member fees under multi-year contracts;... Read more
Hold if already holding. Not a fresh buy at $120.87, but acceptable to hold if already in. Reasons: Concentration risk — Customer: partner contracts (82.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Downgraded from BUY WAIT — price $120.87 vs the analyst target $118.58: -1.9% upside; No upside left. Score 6.8/10, high confidence.
Passes 6/9 gates (positive momentum, news boost analyst 0.60, news boost analyst cluster(4), earnings proximity 96d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: moderate.
About Hinge Health, Inc.
About Hinge Health, Inc.
Hinge Health contracted more than 22 million employer lives and served over 60 health plan and PBM partners as of December 31, 2025, making it one of the larger digital MSK platforms by enrolled population. The company expanded its care platform to 16 affected body areas—from neck to ankle—and launched HingeSelect, an in-person MSK care provider network, in 2025. Net losses reached $528.3 million in fiscal 2025, with an accumulated deficit of $1.05 billion since inception.
Hinge Health earns fees from self-insured employers, fully insured health plan populations, and Medicare Advantage plans under contracts averaging three years in length. Eighty-two percent of 2025 revenue flowed through partner agreements with health plans and PBMs, with Health Care Service Corporation (HCSC), Elevance Health (formerly Anthem), and Aetna Life Insurance Company accounting for 17.5%, 13.7%, and 10.5% of revenue, respectively. The AI-powered care model—anchored by TrueMotion motion tracking technology and the FDA-cleared Enso electrical nerve stimulation wearable—reduced human physical therapy hours by an estimated 97% per 2025 internal data. Revenue is recognized ratably over annual subscriptions, and the company is transitioning certain clients to an engagement-based pricing model that could introduce variability in near-term recognized revenue. Most client contracts are three years in length and health plan partner relationships can be unilaterally terminated before expiration.
Show full overview
The three largest health plan partners—HCSC at 17.5%, Elevance at 13.7%, and Aetna at 10.5% of 2025 revenue—each hold contractual ability to unilaterally terminate their agreements per the 10-K. With 82% of revenue running through partner relationships, a loss of any top-three partner could expose Hinge Health to a revenue gap that its 51-person direct employer sales force may take multiple contract cycles to offset. These three partners each individually exceeded 10% of annual revenue in both 2024 and 2025, indicating sustained rather than one-time dependency.
See also: Healthcare · Health Information Services
From Hinge Health, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Hinge Health, Inc.
Latest news
- NEWS Hinge Health (HNGE) Stock Looks Stretched On Its 156% YTD Run - Yahoo Finance — Yahoo Finance Nov 4, 2026 neutral
- NEWS Hinge Health (HNGE) Stock Looks Above Fair Value After Its 150% Run - Simply Wall St — Simply Wall St Oct 28, 2026 positive
- NEWS Hinge Health (HNGE) Stock Sees Modest Fair Value Lift As Analysts Raise Targets - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Is Hinge Health (HNGE) Undervalued Or Is Its Rally Already Priced In? - Simply Wall Street — Simply Wall Street Sep 30, 2026 positive
- NEWS Is Hinge Health (HNGE) Undervalued Or Is Its Rally Already Priced In? - simplywall.st — simplywall.st Sep 30, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:29:00Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerpartner contracts82%10-K Item 1A: 'Client contracts through our partners accounted for 82% of our revenue for the year ended December 31, 2025'
- LOWCustomerHCSC18%10-K Item 1A: 'client contracts through (i) Health Care Service Corporation ("HCSC") accounted for 17.5% and 17.1% of our revenue, respectively'
- LOWCustomerElevance14%10-K Item 1A: '(ii) Elevance Health, Inc., formerly known as Anthem, Inc. ("Elevance"), accounted for 13.7% and 14.0% of our revenue, respectively'
- LOWCustomerAetna11%10-K Item 1A: '(iii) Aetna Life Insurance Company ("Aetna") accounted for 10.5% and 11.6% of our revenue, respectively'
Material Events(8-K, last 90d)
- 2026-03-17Item 5.02LOWTyler Sloat appointed as Class I Director effective March 16, 2026; named Chair of Compensation Committee and member of Audit Committee. Previously CFO of Freshworks Inc. (since 2020) and Zuora Inc. No departures cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $120.87, but acceptable to hold if already in. Reasons: Concentration risk — Customer: partner contracts (82.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Downgraded from BUY WAIT — price $120.87 vs the analyst target $118.58: -1.9% upside; No upside left. Analyst target $118.58 reached (−1.9%), stop $107.53 (−12.4%), A.R:R -0.1:1. Score 6.8/10, high confidence.
Analyst target $118.58 reached (−1.9% from $120.87); no take-profit level is published. Analyst target $118.58 reached (−1.9%), stop $107.53 (−12.4%), A.R:R -0.1:1. Stop-loss: $107.53.
Concentration risk — Customer: partner contracts (82.0%); Analyst target reached - limited upside remaining; Near 52-week high (3.2% away).
Hinge Health, Inc. trades at a P/E of 32.8 (forward 37.1). TrendMatrix value score: 3.2/10. Verdict: Hold.
23 analysts rate HNGE, with a consensus score of 4.1/5. 16 analysts publish price targets averaging $132.
What does Hinge Health, Inc. do?Hinge Health delivers AI-powered musculoskeletal care through a digital platform serving self-insured employers, health...
Hinge Health delivers AI-powered musculoskeletal care through a digital platform serving self-insured employers, health plans, and Medicare Advantage populations with programs across 16 body areas. Revenue is earned primarily through per-member fees under multi-year contracts; 82% of 2025 revenue was channeled through health plan and PBM partners. The company had over 22 million contracted employer lives and over 60 partners as of December 31, 2025.